Lomustine and Bevacizumab in Progressive GlioblastomaWolfgang Wick, Martin J. van den Bent, Thierry Gorlia et al.|New England Journal of Medicine|2017Cited by 994
LB-05PHASE III TRIAL EXPLORING THE COMBINATION OF BEVACIZUMAB AND LOMUSTINE IN PATIENTS WITH FIRST RECURRENCE OF A GLIOBLASTOMA: THE EORTC 26101 TRIALWolfgang Wick, Martin J. van den Bent, Walter Taal et al.|Neuro-Oncology|2015Cited by 79
EORTC 26101 phase III trial exploring the combination of bevacizumab and lomustine in patients with first progression of a glioblastoma.Wolfgang Wick, Martin J. van den Bent, Alba A. Brandes et al.|Journal of Clinical Oncology|2016Cited by 69
Prognostic Markers of DNA Methylation and Next-Generation Sequencing in Progressive Glioblastoma from the EORTC-26101 TrialTobias Keßler, Antje Wick, Daniel Schrimpf et al.|Clinical Cancer Research|2023Cited by 27
Phase II part of EORTC study 26101: The sequence of bevacizumab and lomustine in patients with first recurrence of a glioblastoma.Wolfgang Wick, Martin J. van den Bent, Roger Stupp et al.|Journal of Clinical Oncology|2016Cited by 19